DR. GEORGE EARL PEOPLES, M.D.
Radiology at Roger Brooke Dr, San Antonio, TX

2011025, Oct 20, 2011

Dec 9, 2009

13/133487

George Peoples - San Antonio TX, US

The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc. - Rockville MD

A61K 39/00, A61P 35/00

4241851

Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods.

2013018, Jul 25, 2013

Jun 27, 2012

13/534550

George PEOPLES - San Antonio TX, US

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD

A61K 39/00, A61K 38/19

4241851, 424 851

The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.

8222214, Jul 17, 2012

Apr 11, 2008

12/602214

George E. Peoples - San Antonio TX, US

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Rockville MD

A61K 38/00

514 194

The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.

2010025, Oct 7, 2010

Dec 21, 2009

12/643509

Robert Humphreys - Acton MA, US
Minzhen Xu - Northborough MA, US
George E. Peoples - San Antonio TX, US

A61K 39/00, A61P 35/00

4241851, 4242771

Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK [SEQ ID NO.: 2] residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.